|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
|
WO2000038721A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
AU2003241629B2
(en)
*
|
1999-04-19 |
2005-06-16 |
Astrazeneca Ab |
An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
|
SE0003766D0
(sv)
*
|
2000-10-18 |
2000-10-18 |
Astrazeneca Ab |
Novel formulation
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002051396A1
(en)
*
|
2000-12-26 |
2002-07-04 |
Sankyo Company, Limited |
Pharmaceutical compositions containing cyclobutene derivatives
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2002329387B2
(en)
|
2001-09-08 |
2007-06-07 |
Albireo Ab |
Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
|
|
IL162533A0
(en)
|
2001-12-19 |
2005-11-20 |
Atherogenics Inc |
Chalcone derivatives and their use to treat diseases
|
|
WO2003053359A2
(en)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
CN100494185C
(zh)
*
|
2002-08-28 |
2009-06-03 |
旭化成制药株式会社 |
新型季铵化合物
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
KR20070026392A
(ko)
|
2004-02-27 |
2007-03-08 |
아사히 가세이 파마 가부시키가이샤 |
신규 벤조티아제핀 및 벤조티에핀 화합물
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
ES2687027T3
(es)
|
2010-11-04 |
2018-10-23 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepáticas
|
|
DK2637646T3
(en)
|
2010-11-08 |
2016-08-29 |
Albireo Ab |
PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
|
|
AU2012328526B2
(en)
|
2011-10-28 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
|
US20130108573A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc. |
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
|
|
CA2907230A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
CN106659726A
(zh)
|
2014-06-25 |
2017-05-10 |
Ea制药株式会社 |
固体制剂及其着色防止或着色减少方法
|
|
EP3197459B1
(en)
*
|
2014-09-28 |
2025-02-12 |
Huahui Health Ltd. |
Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
WO2017138878A1
(en)
|
2016-02-09 |
2017-08-17 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
ES2874669T3
(es)
|
2016-02-09 |
2021-11-05 |
Albireo Ab |
Formulación oral de colestiramina y uso de la misma
|
|
CN108601739B
(zh)
|
2016-02-09 |
2022-01-04 |
阿尔比里奥公司 |
考来烯胺丸剂及其制备方法
|
|
EP3664782B1
(en)
|
2017-08-09 |
2025-01-29 |
Albireo AB |
Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
|
|
CN111032019B
(zh)
|
2017-08-09 |
2022-07-05 |
阿尔比里奥公司 |
考来烯胺颗粒、口服考来烯胺制剂及其用途
|
|
SG11202001685TA
(en)
|
2017-08-28 |
2020-03-30 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
CN112449637B
(zh)
|
2018-06-05 |
2024-03-19 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
PL3810581T3
(pl)
|
2018-06-20 |
2025-04-28 |
Albireo Ab |
Modyfikacje kryształu odewiksibatu
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
IL283190B2
(en)
|
2018-11-21 |
2025-08-01 |
Enanta Pharm Inc |
Functionalized heterocycles as antiviral agents
|
|
TWI835997B
(zh)
|
2019-02-06 |
2024-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻氮呯化合物及其用作膽酸調節劑之用途
|
|
CN118852054A
(zh)
|
2019-02-06 |
2024-10-29 |
阿尔比里奥公司 |
苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
|
|
EP3923943B1
(en)
|
2019-02-12 |
2024-07-31 |
Mirum Pharmaceuticals, Inc. |
Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
|
|
WO2021110883A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP7696898B2
(ja)
|
2019-12-04 |
2025-06-23 |
アルビレオ・アクチボラグ |
ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
EP4069247B1
(en)
|
2019-12-04 |
2025-03-26 |
Albireo AB |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
IL293379B2
(en)
|
2019-12-04 |
2026-04-01 |
Albireo Ab |
Benzothia(dia)azepine compounds and their use as bile acid modulators
|
|
AR120676A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como ácido biliar
|
|
WO2021110884A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
WO2021110887A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
TWI877263B
(zh)
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻二氮呯化合物及其作為膽酸調節劑之用途
|
|
ES2973355T3
(es)
|
2019-12-04 |
2024-06-19 |
Albireo Ab |
Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
|
|
EP4188541B1
(en)
|
2020-08-03 |
2024-12-25 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CA3196488A1
(en)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
CN112274648B
(zh)
*
|
2020-11-23 |
2022-10-14 |
郑州大学 |
一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
|
|
BR112023010799A2
(pt)
|
2020-12-04 |
2023-10-03 |
Albireo Ab |
Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
KR20250022025A
(ko)
|
2022-06-09 |
2025-02-14 |
알비레오 에이비 |
간염 치료
|
|
TW202423921A
(zh)
*
|
2022-08-22 |
2024-06-16 |
美商安塔製藥公司 |
稠合的雜雙環抗病毒劑
|
|
WO2025146508A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2025146507A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|